Last reviewed · How we verify

Fluconazole 150 mg

University of Manitoba · FDA-approved active Small molecule ✓ Verified May 2026 Quality 5/100

Fluconazole 150 mg is a Small molecule drug developed by University of Manitoba. It is currently FDA-approved. Also known as: Diflucan, placebo.

Fluconazole 150 mg is a small molecule inhibitor of the cytochrome P450 51 enzyme, specifically targeting lanosterol 14-alpha demethylase. It is used to treat various fungal infections, including vulvovaginal candidiasis, fungal retinitis, and yeast infections, as indicated by clinical trials on ClinicalTrials.gov.

At a glance

Generic nameFluconazole 150 mg
Also known asDiflucan, placebo
SponsorUniversity of Manitoba
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Fluconazole 150 mg

What is Fluconazole 150 mg?

Fluconazole 150 mg is a Small molecule drug developed by University of Manitoba.

Who makes Fluconazole 150 mg?

Fluconazole 150 mg is developed and marketed by University of Manitoba (see full University of Manitoba pipeline at /company/university-of-manitoba).

Is Fluconazole 150 mg also known as anything else?

Fluconazole 150 mg is also known as Diflucan, placebo.

What development phase is Fluconazole 150 mg in?

Fluconazole 150 mg is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing